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Abstract
Graves’ disease is a form of specific autoimmune disorder in the thyroid organ 
characterized by thyroid-stimulating antibodies (TSAb). Pregnant women are 
the most susceptible to GD due to hormonal changes and tolerance of immune 
responses during pregnancy. The incidence of prematurity, low birth weight 
(LBW), and neonatal thyrotoxicosis risk are the most complications that can 
be acquired if treatment is late and inadequate. It has implications for increased 
fetomaternal morbidity and mortality. Apart from being a biomarker for definitive 
diagnosis, TSAb testing is also beneficial for assessing treatment response and pre-
dicting relapse of GD (relapse) after oral anti-thyroid treatment. GD patients with 
high TPOAb titers also tend to have a high relapse rate. However, the evaluation 
of both TSAb and TPOAb examinations during and after treatment is rarely done 
routinely due to the examination’s high cost. This works proposed developing TSHR 
and TPO antigen-based rapid diagnostic tests through the immunochromatography 
method to address the challenges of financing and limited laboratory facilities in 
the area. Besides, understanding the importance of examining thyroid antibodies 
(TSAb and TPOAb) and interpretation in clinical practice is still a matter of debate 
in clinical circles, so it requires in-depth information.
Keywords: Graves’s disease, thyroid-stimulating antibodies, thyroid peroxidase, 
pregnant women
1. Introduction
Improved hygiene and technological advances in several developed and develop-
ing countries have implications for health improvements marked by a decrease in 
the population’s infectious diseases. However, on the other hand, the tendency of 
autoimmune disease [1] and cancer [2] is increasingly being found with the avail-
ability of early detection screening tools. Genetic susceptibility, nutrition, and 
environmental factors are risk factors for the increasing prevalence and incidence of 
autoimmune diseases in the population [3, 4].
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Autoimmune cases in specific thyroid organs are the second-highest after 
rheumatoid arthritis [1], with an incidence rate of about 2–5% affecting the world 
population [5]. Based on screening data from US and European populations, it was 
reported that autoimmune thyroid diseases such as Graves’ disease were more dom-
inant in women than men with a ratio of 5: 1 [6, 7]. The cause of the predominant 
tendency of women to develop autoimmune disorders is still being debated. Several 
hypotheses are associated with the structure of the X chromosome and hormonal 
changes. Morphologically, the X chromosome is larger and contains more genes 
(800–900 genes) than Y chromosomes (50–60 genes). Most of the genes related to 
immune system response and regulators are present on the X chromosome so that 
women have a higher risk of developing autoimmune disorders than men who only 
have one X chromosome [8, 9].
2. Graves’ disease in pregnancy
Graves’ Disease (GD) is a form of specific autoimmune disorder in the thyroid 
organ characterized by the formation of thyroid-stimulating antibodies (TSAb) and 
increased thyroid hormone secretion (hyperthyroidism) [10]. This disorder was 
first introduced by Robert James Graves in 1835, who has clinical features such as 
goiter, palpitations, and orbitopathy [11]. About 60–80% of hyperthyroid disorders 
in the population are due to GD [12], with an incidence of 1–2 cases occurring in 
1000 pregnancies [13]. GD disorders can affect all age groups, both children [14], 
reproductive age [15], and the elderly [16], but the most incidence occurs in women 
aged 20–49 years [6, 17].
Pregnant women are the most susceptible to GD, which is thought to be due to 
decreased immune tolerance during pregnancy [18] and hormonal changes [19]. 
Approximately 0.4%-1.0% of women of reproductive age have GD before preg-
nancy, and 0.2% have it during pregnancy [13]. The American Thyroid Association 
(ATA) has issued recommendations for routine thyroid health screening in preg-
nant women, especially the first trimester of pregnancy and postpartum [20]. 
Besides, all women of reproductive age who are suffering from GD or have a previ-
ous history of GD are encouraged to seek counseling when planning pregnancy as 
an effort to improve fetomaternal health [19].
The high titer of maternal TSAb that can cross the placental barrier will mani-
fest in impaired fetal thyroid function, increasing fetomaternal morbidity, and 
mortality [18, 21]. Preterm birth (prematurity) [22], low birth weight (LBW) 
[21, 22], and risk of neonatal thyrotoxicosis [23] are some of the frequently 
reported fetomaternal complications. Apart from TSAb testing, the ATA also 
recommends that pregnant women with a positive TPOAb be advised to evaluate 
serum TSH levels every four weeks during the second trimester [20].
3. TSHR and TPO as autoantigen
Genetically, polymorphisms in the thyroid-stimulating hormone receptor 
(TSHR) gene found on chromosome 14q31 [24–26] and the thyroid peroxidase 
gene on chromosome 2p25 (TPO) [27, 28] are closely related to susceptibility and 
severity of GD disease in various populations. Both thyroid-specific genes can act 
as autoantigens and are potential genetic biomarkers for GD [29, 30]. The term 
autoantigen indicates that a protein originates within the individual’s own body, has 
a highly conserved structure, and is coded for genes with a low mutation rate. Thus, 
autoantigen is not an abnormal molecule but is coded only for genes that undergo 
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polymorphisms in the population. Polymorphisms cause variations in protein 
structure and function so that they are sometimes recognized as foreign antigens 
that can interact with T lymphocytes and antibodies [31, 32].
Thyroid-stimulating hormone receptor (TSHR) is a protein molecule that plays 
a vital role in the growth and differentiation of the thyroid gland and is directly 
involved in signal transduction and regulation of thyroid hormone biosynthesis 
[33, 34]. TSHR protein is the primary autoantigen that triggers GD and is a target 
that is attacked by TSAb [35]. T lymphocyte immunotolerance’s failure to the TSHR 
antigen triggers the infiltration of lymphocytes, dendritic cells, and macrophages 
into the thyroid follicle. Furthermore, lymphocyte infiltration triggers the secre-
tion of several pro-inflammatory cytokines such as interleukin 1ß, IL-6, IL-12 
interferon-ƴ, ligand CD40, and tumor necrosis factor-α. Presentation of TSHR 
peptides by dendritic cells on MHC-II molecules will activate B cells and differenti-
ate plasma cells to synthesize and secrete TSAb into the circulation [10, 36]. TSAb 
protein, which mimics the action of TSH on the surface of the thyroid follicle cells, 
is the leading cause of thyroid hyperplasia and hyperfunctioning of T3 and T4 
secretion becomes uncontrolled [37].
In the majority of people with GD, other autoantibodies can also be found, such 
as thyroid peroxidase antibody (TPOAb) [38, 39]. Thyroid peroxidase (TPO) is 
the main enzyme that assists in the biosynthesis of thyroid hormones. The TPO 
enzyme catalyzes the organization of iodine (iodination) and the coupling process 
of iodothyrosine residues in thyroglobulin [40]. In GD, the persistent lymphocyte 
infiltration of the thyroid follicular cells can also trigger a failure to tolerate the 
TPO autoantigen’s immune response. About 80% of people with GD have positive 
TPOAb, which can activate the complement cascade, causing thyroid gland damage 
and dysfunction [38, 41]. Physiologically, the presence of TPOAb can also be found 
in normal populations around 10%-15% [42, 43], and in thyroid malignancies 
around 10%-20% [41].
Although both autoantibodies cross the placental barrier, only maternal 
TSAb titer can interfere with fetal and neonatal thyroid function. In contrast, 
the presence of TPOAb does not significantly affect neonatal thyroid function 
[20, 44]. However, monitoring of thyroid antibody titer and regular counseling 
is necessary during pregnancy due to complications of morbidity in the mother 
and infant [20, 45].
4. The role of TSAb and TPOAb in early-onset and relapse investigation
The early diagnosis of thyrotoxicosis is a challenge for clinicians because of the 
atypical clinical features and parallels the physiological changes in normal preg-
nancy [18]. Total T3, free T4, and TSH levels established during pregnancy also have 
different parameters or reference values  from non-gravidas [46, 47]. The cause of 
thyrotoxicosis during pregnancy must be identified immediately, and must be able 
to differentiate between GD and other non-autoimmune hyperthyroidism such as 
gestational transient thyrotoxicosis (GTT) [13]. Although serum human chorionic 
gonadotropin (hCG) levels were higher in GTT patients compared to GD, this 
parameter is not typical in the early phase, so TSAb examination can be indicated to 
differentiate the cause of thyrotoxicosis [20].
The presence of TSAb in serum is a hallmark or the primary marker in the 
diagnosis of GD. More than 95% of the presence of TSAb can be found in serum 
with GD [31, 48]. The presence of TSAb can be detected in the early phase of GD 
before causing characteristic clinical symptoms (asymptomatic), and the titer will 
continue to increase if not handled adequately [44]. Apart from the diagnostic 
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screening for GD, TSAb measurement is also useful for predicting cases of GD 
relapse after stopping treatment [37, 49]. The research of Kwon et al. (2016) found 
that only TSAb measurements could predict cases of GD relapse, while the thyro-
tropin-binding inhibitory immunoglobulin (TBII) examination was insensitive to 
relapsing GD cases [49]. Although the use of thionamide anti-thyroid drugs such as 
propylthiouracil (PTU) and methimazole (MMI) has an immunomodulatory effect 
of lowering TSAb titers [50], many reports of remission after treatment [51–54]. 
Carella et al. reported that TSAb titers remained positive in the majority of GD 
patients after 18 months of treatment with Methimazole (MMI) [51].
Increased TSAb titer also affects extrathyroid clinical manifestations, such as 
orbitopathy [55] and dermopathy (pretibial myxedema) [56], which can increase 
morbidity and decrease the quality of life for Graves sufferers. Bahn stated that 
TSAb titers have diagnostic value in euthyroid patients with exophthalmic [57].
In addition, TSAb measurement can also be used to determine treatment 
response (monitoring) and prognosis of Grave’s disease patients who have been 
treated with oral anti-thyroid [52, 58].
TSAb examination in pregnant women suffering from GD or post anti-thyroid 
treatment can predict the likelihood of neonatal thyrotoxicosis [59, 60]. Pregnant 
women who have high TSAb titers and persist until the third trimester require 
special monitoring of neonates and mothers because of their increased risk of 
thyrotoxicosis [37]. The results of research by Hamada et al. showed that patients 
with GD with a history of radioactive iodine therapy (I-131) had a higher TSAb titer 
during pregnancy and were at risk of delivering babies with thyrotoxicosis [61].
Positive TPO autoantibodies can also be found in GD abnormalities, even though 
a change in titer can predict recurrence of GD after anti-thyroid treatment [27]. 
TPOAb titers are less specific than TSAb in determining the diagnosis of GD. This is 
because, in certain levels, TPOAb titer can be found in the serum of normal indi-
viduals (euthyroid) and pregnant women without autoimmune thyroid disorders. 
The prevalence of both reaches 15% in the average population and 14% in pregnant 
women [42, 43]. This percentage affects the clinical specificity of TPOAb as a 
diagnostic indicator for the detection of AITD.
Interestingly, TPOAb titers were also found in people with GD, which suggests 
an association with the course of thyroiditis. Umar et al. found that 15–20% of 
Grave’s patients had spontaneous hypothyroidism as a result of chronic thyroiditis 
(Hashimoto), and suspected that the widespread immune response in Grave’s 
episode would trigger an increase in TPO and Tg autoantibodies, causing marked 
thyroiditis. With lymphocyte infiltration in thyrocytes cells [62].
5. Development of TSAb and TPOAb measurement methods
In recent decades, methods of measuring thyroid antibodies have continued 
to evolve, ranging from semiquantitative testing via agglutination and comple-
ment fixation tests [63, 64], to ligand-specific testing using recombinant antigens 
and cultured cells transfected with human TSHR [65, 66]. The hemagglutination 
method is rarely used and has many shortcomings in terms of specificity, sensitiv-
ity and depending on operator skills (subjective). Current examination methods 
have better precision because they directly measure autoantigen and autoantibody 
interactions with high sensitivity and specificity [67].
Currently, there are two methods that are often used to detect the pres-
ence of TSHR autoantibodies, namely (i) the TBII test (TSH Binding Inhibition 
Immunoglobulin), also known as the TRAb test, which is a test to assess the capacity 
of a patient’s serum or IgG to inhibit TSH receptor binding with TSH labeled I125 
5
Thyroid Peroxidase (TPO) and Thyroid Stimulating Hormone Receptor (TSHR) Based…
DOI: http://dx.doi.org/10.5772/intechopen.96509
or against recombinant TSHR protein expressed on CHO (Chinese Hamster Ovary) 
cells [37, 66]. (ii) A functional test (bioassay) to detect the presence of TSAb 
(stimulation) or TBAb (inhibition), using intact cells that are transfected with chi-
meric or human TSH receptors, which will then produce a biological response in the 
form of an increase in cAMP or bioreporter (luciferase) genes as markers. Biological 
activity against TSAb or TBAb activity in patient serum [68].
The TRAb method can detect TSHR autoantibodies that interact with the TSH 
receptor, regardless of their functional character (stimulation or inhibition). This 
method works based on competitive binding, i.e., the immunoglobulin in the patient’s 
serum will compete with either porcine (porcine) or bovine TSH that is a radiolabeled 
or human monoclonal antibody (code M22) which binds to the TSH receptor (recombi-
nant human TSHR) (Figure 1) [66, 67]. In its development, the third generation TRAb 
test uses a monoclonal antibody that binds to TSH (M22). In the research of Zöphel 
et al. proved that the sensitivity of using human TSHR monoclonal antibody M22 
(90.3%, positive cutoff 0.32 IU / I) was better than that of bovine TSH (62.9%, positive 
cutoff 1.64 IU/I) [66]. The results of a meta-analysis study conducted by Tozzoli, et al. 
showed that the sensitivity and specificity of the third generation TRAb test (98.3% 
and 99.2%) were higher than the second generation (97.1% and 97.4%) [67].
The second method is bioassay (TSAb or TBAb), which uses intact cells trans-
fected with chimeric or human TSH receptors, which will produce a biological 
response in the form of an increase in cAMP or a bioreporter gene (luciferase) as 
a biological marker of stimulating or inhibiting TSHR antibody activity in serum 
patient [68]. This method is a functional examination, which can technically be 
modified to detect the presence of TSAb or TBAb that are present together in a 
patient’s serum. The development of a second-generation bioassay method using 
a mouse/human chimeric TSHR-LH receptor (MC4) can effectively eliminate the 
effect of TBAb. This approach demonstrates sufficient specificity and sensitivity for 
the diagnosis of GD and is clinically useful for monitoring the effect of anti-thyroid 
treatment (relapse and remission) [69].
One of the modalities of the bioassay method introduced recently and widely 
used in research is Thyretain, a method of measuring TSAb activity with a 
luciferase bioreporter using chimeric TSH-LH receptors (MC4) expressed on the 
surface of CHO (MC4-CHO-Luc) cells (Figure 2). In MC4, C-terminal TSHR 
Figure 1. 
Schematic illustration of TSHR autoantibodies detection with competitive binding of TSH receptor with 
radiolabelled or human monoclonal antibody (code: M22) [68].
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(amino acid 262–335) is substituted with amino acids 261–329 derived from the 
mouse LH-hCG (luteinizing hormone-choriogonadotropin) receptor. The substi-
tuted TSHR C-terminal area contains the epitope TBAb. The MC4 receptor was 
designed to reduce TBAb interactions when TSAb was measured, by eliminating 
the epitope area of TSHR using TBAb. When TSAb binds to the MC4 receptor on 
CHO-MC4 cells, it produces a cascade signal that stimulates increased intracel-
lular cAMP production. Furthermore, cAMP induces activation of a promoter 
containing the luciferase gene CRE-luc (cAMP response element-luciferase). 
Luciferase activity is measured as a relative light unit, determined in cell-lysate 
through a luminometer [69–71].
Initially, TPO autoantibodies were detected as antibodies to thyroid micro-
some or AMA (anti microsomal antibody), using the semiquantitative method of 
erythrocyte hemagglutination and complement fixation [63]. The development of 
more specific detection methods is done by immunoassay or immunometric, using 
recombinant or purified TPO [72]. A recent study by D’Aurizio et al. evaluating and 
developing the diagnostic performance of third-generation immunometric meth-
ods, obtained increased sensitivity and specificity that are better than before [73].
Although many benefits can be obtained from regular TSAb and TPOAb titer 
checks in pregnant women who are suffering from GD or who have a history of GD 
before pregnancy. However, in reality, most clinicians have not routinely performed 
thyroid antibody tests, of course, with various considerations such as the high cost 
of examinations. Not all laboratory facilities can carry out TSAb examinations.
Figure 2. 
Schematic illustration of measuring TSAb activity with a luciferase bioreporter chimeric TSH-LH 
receptor [69].
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